Search

everythinglearnresearchcommunity

for

Search:↓

The study investigated ZSYY001, a polymeric micellar paclitaxel formulation, in preclinical and phase I trials for advanced solid tumors. Preclinical tests on xenograft models showed significant tumor growth inhibition without weight loss. In the phase I trial, involving 18 patients, ZSYY001 was administered at doses up to 390 mg/m² without premedication, and no dose-limiting toxicities were observed. Common side effects included anemia and hair loss, but no acute hypersensitivity reactions occurred. The study found two partial responses and seven cases of stable disease, indicating promising antitumor activity. ZSYY001 was deemed safe, well-tolerated, and exhibited non-linear pharmacokinetics, suggesting it as a potential treatment option.

This retrospective case series evaluated the efficacy and safety of dual-targeted therapy (DTT) in 18 patients with refractory inflammatory bowel disease (IBD) across three tertiary hospitals in China. The study included 8 patients with ulcerative colitis and 10 with Crohn’s disease, using combinations of biologic agents and tofacitinib. Results showed high clinical response rates of 88.23% at 3 months, 91.67% at 6 months, and 100% at 9 months, with an endoscopic response in 88.89% of evaluated patients at 9 months. Adverse events were minimal, with some patients experiencing ustekinumab-associated arthralgia and alopecia, and tofacitinib-related allergic purpura, leading to a transition to monotherapy. Two patients developed infections but continued DTT after treatment. The study concludes that DTT is a promising and safe option for patients unresponsive to conventional monotherapies.